SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as investors aggressively target the stock due to a combination of extreme short interest, a very low tradable float, and high-frequency volatility that has triggered multiple trading halts. The community is heavily divided, with bulls pointing to a classic short squeeze setup and potential momentum, while bears highlight historical reverse splits, lack of consistent profitability, and concerns over a potential pump-and-dump scheme.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is trending due to significant volatility following a reverse stock split, with traders closely monitoring the ticker as a potential low-float play. The community remains deeply divided, with some betting on parabolic squeeze mechanics while others caution against the stock's fundamental weaknesses and the risk of further dilution.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to a combination of a newly announced licensing agreement and a private placement, driving intense retail speculation about a potential short squeeze. Community members are actively debating the sustainability of these gains, weighing the volatility against concerns regarding share dilution and the stock's long-term clinical pipeline.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market scrutinizes its April delivery results, which triggered volatility amid ongoing debates about the companys growth trajectory, competitive landscape, and aggressive institutional short activity. Investors remain deeply divided, with many debating the impact of upcoming model launches and profitability against persistent concerns regarding market manipulation and sector-wide headwinds.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are currently in the spotlight as investors react to a significant earnings beat, with the community actively debating whether the platform's high-margin monetization and AI ad-tool potential will finally overcome ongoing price volatility and institutional short positioning.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is facing significant downward pressure following a downward revision to its annual bookings forecast, as new safety and age-verification protocols impact user growth and engagement. While some investors see the pullback as an attractive entry point for long-term growth, others remain cautious, highlighting the competitive gaming landscape and broader market skepticism regarding the company's path to consistent profitability.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending following a NOAA determination that the company's deep-seabed mining application is in full compliance, sparking significant community excitement about accelerated permitting and long-term supply dominance. Investors are actively discussing the potential for a major reversal, with many highlighting this milestone as a critical step toward commercial recovery while keeping a close watch for upcoming definitive agreements and further regulatory progress.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing intense market activity as investors weigh its aggressive turnaround efforts, including the expansion of foundry operations and high-profile leadership shifts, against community debate over its valuation. While bullish participants highlight strategic government backing and manufacturing progress as catalysts for long-term growth, many voices in the community express skepticism, frequently citing the potential for a short-term pullback following recent parabolic moves.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is experiencing intense volatility driven by speculative momentum, institutional accumulation, and ongoing debate over its high valuation relative to its current revenue. While bullish investors point to its critical role in AI-focused optical infrastructure as a catalyst for future growth, the community remains deeply divided, with many bears highlighting significant insider selling, persistent lack of profitability, and the threat of upcoming share dilution as clear warning signs of an unsustainable bubble.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors react to its successful pivot toward AI and cloud infrastructure, highlighted by a strong earnings report and strategic partnerships that suggest a significant business transformation. The community is actively discussing the stock's long-term potential as a re-rated AI infrastructure play, with many traders leaning into bullish call positions to capitalize on what they perceive as a durable shift in the company's growth trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Following the transaction, Geert R. owns 120,815 shares of the company.&nbsp;</li><li>Cel-Sci is most known for its experimental cancer treatment called Multikine.</li><li>The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients.</li></ul>Shares of CEL-SCI Corp. (CVM) rallied 7% on Monday after its CEO Kersten Geert R. purchased 38,023 shares of restricted stock directly from the Company.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/725363/000123603026000002/xslF345X05/primary_doc.xml">filing</a> with the U.S. Securities and Exchange Commission, Geert made the purchase on Jan. 22 at the closing price on Jan 21 or $5.26 per share.This transaction amounts to about $200,000. Following the transaction, the CEO owns 120,815 shares of the company.<h2 class="st-heading-2">Cel-Sci’s Pipeline</h2>Cel-Sci is known for its experimental cancer treatment, Multikine. It is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy.The company is currently preparing to conduct a confirmatory registration study for the treatment which will enroll 212 patients with newly diagnosed locally advanced not yet treated resectable head and neck cancer. Enrollment is expected to begin for the trial in spring 2026 and the company intends to seek approval based on data generated by 2028.During the fiscal year ended September, the company reported a net loss of $25.4 million, down from the $27.6 million reported in fiscal 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CVM stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said the stock is one to “watch closely.”<stembedurl>https://www.stocktwits.com/topstockalerts/message/642897665</stembedurl>Another highlighted that Vanguard Group had previously disclosed ownership of the stock. “Big Money has moved in here for a reason,” they said.<stembedurl>https://www.stocktwits.com/itsverified/message/642877607</stembedurl><a href="https://stocktwits.com/symbol/CVM">CVM stock</a> has dropped nearly 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iova-shares-jump-whats-retail-expecting/cmy76S5R4h0">IOVA Shares Jump 8% — What’s Retail Expecting?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cel-Sci logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why DID CVM Shares Rally Over 7% Today?

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.

Equity

According to a filing with the U.S. Securities and Exchange Commission, CEO Kersten Geert R. purchased 38,023 shares in the company on Jan. 22 at $5.26 per share.


Retail chatter picked up on Cel-Sci Corporation on Wednesday as investors awaited a key decision from the Saudi Food and Drug Authority (SFDA) on the company’s application for Breakthrough Medicine Designation for its cancer immunotherapy, Multikine.&nbsp;The ruling could come soon, as the SFDA’s 60-day review window is nearing its close.In August, Cel-Sci signed a Memorandum of Understanding with a leading Saudi pharmaceutical company, which submitted the application to the SFDA. A final commercialization agreement between the two partners is expected in the third quarter of 2025. The Saudi partner is also expected to facilitate reimbursement and accelerate Multikine’s sale and patient access in the Kingdom.The move has drawn growing interest from Saudi investment funds looking to back Multikine and Cel-Sci’s expansion across the Middle East and North Africa region.Multikine is designed to strengthen a patient’s immune system before surgery for newly diagnosed, untreated head and neck cancer. In a global Phase 3 study, the largest of its kind, the therapy improved five-year survival rates to 73% from 45% among patients receiving standard care alone, cutting the risk of death by half.If approved, Multikine would qualify for accelerated patient access and reimbursement under Saudi Arabia’s Breakthrough Medicine Program, which aims to fast-track treatments for serious or life-threatening diseases that meet unmet medical needs.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that Cel-Sci’s April update indicated the company was encouraged to seek conditional approval under the Breakthrough Therapy Designation. The filing was made around mid-August, suggesting a decision could be imminent.<stembedurl>https://stocktwits.com/NavyPatrol657/message/632324726</stembedurl>Another user expressed anticipation for an update from CEO Geert Kersten, while a third observed that the stock might remain subdued until the SFDA announcement.<stembedurl>https://stocktwits.com/prophet777/message/632356422</stembedurl><stembedurl>https://stocktwits.com/NoobFriendly/message/632216212</stembedurl><a href="https://stocktwits.com/symbol/CVM">CEL-SCI Corporation’s stock</a> has declined 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEL-SCI Corporation’s stock (CVM) has declined 18% so far in 2025.| Image source: Getty Images

Retail Buzz Builds Around Cel-Sci Stock Ahead Of Saudi Ruling On Cancer Drug Multikine

Multikine is a cancer immunotherapy, which has significantly improved survival in head and neck cancer patients during global Phase 3 trials.

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical companies for a partnership that spans regulatory and commercial activities for Multikine in the Kingdom of Saudi Arabia.<a href="https://stocktwits.com/symbol/CVM">CEL-SCI</a>’s shares were trading 33% higher at the time of writing.The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250711051288/en/CEL-SCI-to-Sign-Partnership-Agreement-With-Leading-Saudi-Arabian-Pharma-Company-for-Multikine-in-the-Treatment-of-Head-Neck-Cancer">said</a>. The partner will then file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA).Multikine is a cancer drug administered before surgery as a treatment for newly diagnosed and previously untreated head and neck cancer.If granted Breakthrough Medicine Designation, Multikine would immediately become available for patient access, reimbursement, or sale in Saudi Arabia. CEL-SCI said that it believes Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and is now developing a comprehensive commercialization plan with its Saudi pharma partner.In a study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% versus 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.The drug, given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.CEL-SCI also said on Friday that several Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.On Stocktwits, retail sentiment around CVM jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_11_59_25_AM_png_2f84b0779d.webp" alt="CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>CVM's Sentiment Meter and Message Volume as of 12 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>CVM stock is down by 58% this year and by over 86% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-reportedly-stands-firm-on-eu-ad-model/ch8cirOR5Zw">Meta Reportedly Stands Firm On EU Ad Model Amid Looming Regulatory Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Shares of Cel-Sci Corp ($CVM) slipped in the after-hours trading session on Friday following the company’s announcement of a share offering, with retail sentiment staying neutral. The purchase price of the offering, for its common stock par value of $0.01 per share, wasn’t immediately known. The last reported sale price of its stock was $0.70 per share. According to the company’s filing with the SEC, it is offering potential purchasers, along with related parties who own more than 4.99% of its outstanding common stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants exercisable at an exercise price of $0.01 per share.The purchase price of each pre-funded warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01, the statement said.The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full, the statement added. For each warrant, the number of shares of common stock on offer will be decreased on a one-for-one basis.&nbsp; Retail sentiment on Stocktwits has been ‘neutral’ compared to a week ago. Message volumes have been in the normal range. &nbsp;<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_11_21_09_AM_2d60d70bed.png" alt="Screenshot 2024-12-30 at 11.21.09 AM.png" width="1256" height="302"><figcaption>CVM sentiment meter and message volumes on Dec 29</figcaption></figure><stembedurl>https://stocktwits.com/phoenix31415/message/598120019</stembedurl>A ‘bearish’ commenter was not convinced on the terms.<stembedurl>https://stocktwits.com/ThaDreadPirate/message/598079934</stembedurl>The company has engaged ThinkEquity as the placement agent in connection with this offering.Cel-Sci develops immunotherapy products for the treatment of cancer and infectious diseases.Cel-Sci stock is down 77% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

CVM
Cel-Sci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVM News

CVMCel-Sci Corp